Skip to main content
SpringerLink
Log in
Book cover

Metastasis of Breast Cancer pp 203–217Cite as

The insulin-like growth factor-1 ligand in breast cancer management

  • Chapter

Part of the book series: Cancer Metastasis – Biology and Treatment ((CMBT,volume 11))

Abstract

The insulin-like growth factor-1 (IGF-1) system plays an important role in normal human development and is also a potent mitogen which can stimulate the development and progression of breast cancer cells. This review aims at looks at how measuring IGF-1 levels may be used in the clinical management of breast cancer patients. Many studies have shown that IGF-1 acts synergistically with oestrogen to stimulate breast cancer cells. Case-control studies have also shown that premenopausal women with high levels of serum IGF-1 have a high risk of developing breast cancer later in life which does not apply to postmenopausal women with correspondingly high serum levels. Serum IGF-1 levels can therefore potentially be used as biomarkers for predicting breast cancer risk while some studies have started using serum IGF-1 levels as a response biomarker for chemopreventive drug trials. Measuring IGF-1 ligand expression in breast cancer tissue is not consistently associated with better or worst prognosis features. Identifying the IGF-1 gene polymorphism can potentially be used in predicting breast cancer risk and 17beta HSD 1 inhibitors is underway with promising initial results.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

7references

  1. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 2002; 63(4):317-332.

    Article  PubMed  CAS  Google Scholar 

  2. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195(2):127-137.

    PubMed  CAS  Google Scholar 

  3. Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL, et al. Recovery of growth hormone release from suppression by exogenous insulinlike growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I. J Clin Endocrinol Metab 1998; 83(8):2836-2842.

    Article  PubMed  CAS  Google Scholar 

  4. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15(1):80-101.

    PubMed  CAS  Google Scholar 

  5. PEARSON OH, RAY BS. Results of hypophysectomy in the treatment of metastatic mammary carcinoma. Cancer 1959; 12(1):85-92.

    Article  PubMed  CAS  Google Scholar 

  6. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003; 63(15):4384-4388.

    PubMed  CAS  Google Scholar 

  7. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochem Biophys Acta 1997; 1332(3):F105-F126.

    PubMed  CAS  Google Scholar 

  8. Long L, Rubin R, Baserga R, Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 1995; 55(5):1006-1009.

    PubMed  CAS  Google Scholar 

  9. Guerra FK, Eijan AM, Puricelli L, Alonso DF, Bal de Kier JE, Kornblihgtt AR, et al. Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Int J Cancer 1996; 65(6):812-820.

    Article  PubMed  CAS  Google Scholar 

  10. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000; 57(7):1050-1093.

    Article  PubMed  CAS  Google Scholar 

  11. Resnicoff M, Baserga R. The role of the insulin-like growth factor I receptor in transformation and apoptosis. Ann N Y Acad Sci 1998; 842:76-81.

    Article  PubMed  CAS  Google Scholar 

  12. Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. 2. Breast Cancer Res Treat 1998; 47(3):209-217.

    Article  PubMed  CAS  Google Scholar 

  13. Guo YS, Jin GF, Houston CW, Thompson JC, Townsend CM, Jr. Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells. J Cell Physiol 1998; 175(2):141-148.

    Article  PubMed  CAS  Google Scholar 

  14. Geier A, Beery R, Haimsohn M, Karasik A. Insulin-like growth factor-1 inhibits cell death induced by anticancer drugs in the MCF-7 cells: involvement of growth factors in drug resistance. Cancer Invest 1995; 13(5):480-486.

    Article  PubMed  CAS  Google Scholar 

  15. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination 8. Clin Cancer Res 2004; 10(1 Pt 2):346-354.

    Article  Google Scholar 

  16. Nicholson RI, Johnston SR. Endocrine therapy-current benefits and limitations. Breast Cancer Res Treat 2005; 93; 1: 3-10.

    Article  CAS  Google Scholar 

  17. Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr Relat Cancer 2004; 11(4):623-641.

    Article  PubMed  CAS  Google Scholar 

  18. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351(9113):1393-1396.

    Article  PubMed  CAS  Google Scholar 

  19. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, et al. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989; 3(3):509-517.

    Article  PubMed  CAS  Google Scholar 

  20. Ellis MJ, Jenkins S, Hanfelt J, Redington ME, Taylor M, Leek R, et al. Insulin- like growth factors in human breast cancer. Breast Cancer Res Treat 1998; 52 (1-3):175-184.

    Article  PubMed  CAS  Google Scholar 

  21. Voskuil DW, Bosma A, Vrieling A, Rookus MA, ’t Veer LJ. Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat 2004; 84(3):225-233.

    Article  PubMed  CAS  Google Scholar 

  22. Gebauer G, Jager W, Lang N. mRNA expression of components of the insulin- like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells. Anticancer Res 1998; 18(2A):1191-1195.

    PubMed  CAS  Google Scholar 

  23. Chong YM, Williams SL, Elkak A, Sharma AK, Mokbel K. Insulin-like growth factor 1 (IGF-1) and its receptor mRNA levels in breast cancer and adjacent non-neoplastic tissue. Anticancer Res 2006; 26(1A):167-173.

    PubMed  CAS  Google Scholar 

  24. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999; 96(12):7088-7092.

    Article  PubMed  CAS  Google Scholar 

  25. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, et al. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 1994; 269(23):16433-16442.

    PubMed  CAS  Google Scholar 

  26. Richards RG, Walker MP, Sebastian J, DiAugustine RP. Insulin-like growth factor-1 (IGF-1) receptor-insulin receptor substrate complexes in the uterus. Altered signaling response to estradiol in the IGF-1(m/m) mouse. J Biol Chem 1998; 273(19):11962-11969.

    Article  PubMed  CAS  Google Scholar 

  27. Stewart AJ, Johnson MD, May FE, Westley BR. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen- stimulated proliferation of human breast cancer cells. J Biol Chem 1990; 265(34):21172-21178.

    PubMed  CAS  Google Scholar 

  28. Dupont J, Karas M, LeRoith D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem 2000; 275(46):35893-35901.

    Article  PubMed  CAS  Google Scholar 

  29. Ruan W, Catanese V, Wieczorek R, Feldman M, Kleinberg DL. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 1995; 136(3):1296-1302.

    Article  PubMed  CAS  Google Scholar 

  30. Guvakova MA, Surmacz E. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell- cell adhesion in human breast cancer cells. Exp Cell Res 1997; 231(1):149-162.

    Article  PubMed  CAS  Google Scholar 

  31. Kleinman D, Karas M, Roberts CT, Jr., LeRoith D, Phillip M, Segev Y, et al. Modulation of insulin-like growth factor I (IGF-I) receptors and membraneassociated IGF-binding proteins in endometrial cancer cells by estradiol. Endocrinology 1995; 136(6):2531-2537.

    Article  PubMed  CAS  Google Scholar 

  32. Teruel T, Valverde AM, Benito M, Lorenzo M. Insulin-like growth factor I and insulin induce adipogenic-related gene expression in fetal brown adipocyte primary cultures. Biochem J 1996; 319 ( Pt 2):627-632.

    PubMed  CAS  Google Scholar 

  33. Valverde AM, Lorenzo M, Navarro P, Benito M. Phosphatidylinositol 3-kinase is a requirement for insulin-like growth factor I-induced differentiation, but not for mitogenesis, in fetal brown adipocytes. Mol Endocrinol 1997; 11(5): 595-607.

    Article  PubMed  CAS  Google Scholar 

  34. Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, et al. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990; 82(21):1693-1697.

    Article  PubMed  CAS  Google Scholar 

  35. Lonning PE, Hall K, Aakvaag A, Lien EA. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 1992; 52(17):4719-4723.

    PubMed  CAS  Google Scholar 

  36. Colletti RB, Roberts JD, Devlin JT, Copeland KC. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 1989; 49(7):1882-1884.

    PubMed  CAS  Google Scholar 

  37. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92(18):1472-1489.

    Article  PubMed  CAS  Google Scholar 

  38. Chong YM, Colston K, Jiang WG, Sharma AK, Mokbel K. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue. Breast Cancer Res Treat 2006 Jun 5.

    Google Scholar 

  39. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005; 57(3):359-383.

    Article  PubMed  CAS  Google Scholar 

  40. Giudice LC, Dsupin BA, Gargosky SE, Rosenfeld RG, Irwin JC. The insulin- like growth factor system in human peritoneal fluid: its effects on endometrial stromal cells and its potential relevance to endometriosis. J Clin Endocrinol Metab 1994; 79(5):1284-1293.

    Article  PubMed  CAS  Google Scholar 

  41. Kudoh M, Susaki Y, Ideyama Y, Nanya T, Mori M, Shikama H. Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insulin-like growth factor-I gene expression in rats with experimental endometriosis. J Steroid Biochem Mol Biol 1997; 63(1-3):75-80.

    Article  PubMed  CAS  Google Scholar 

  42. Wennbo H, Tornell J. The role of prolactin and growth hormone in breast cancer. Oncogene 2000; 19(8):1072-1076.

    Article  PubMed  CAS  Google Scholar 

  43. Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R, Rosen JM. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene 2000; 19(7):889-898.

    Article  PubMed  CAS  Google Scholar 

  44. Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med 1997; 3(10):1141-1144.

    Article  PubMed  CAS  Google Scholar 

  45. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14(3):699-704.

    Article  PubMed  CAS  Google Scholar 

  46. Allen NE, Roddam AW, Allen DS, Fentiman IS, Dos SS, I, Peto J, et al. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF- binding protein-3 and breast cancer risk. Br J Cancer 2005; 92(7):1283-1287.

    Article  PubMed  CAS  Google Scholar 

  47. Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 2002; 11(12):1566-1573.

    PubMed  CAS  Google Scholar 

  48. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000; 88(5):828-832.

    Article  PubMed  CAS  Google Scholar 

  49. Li BD, Khosravi MJ, Berkel HJ, Diamandi A, Dayton MA, Smith M, et al. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 2001; 91(5):736-739.

    Article  PubMed  CAS  Google Scholar 

  50. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, van Gils CH, Van Noord PA, Rinaldi S, et al. Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 2003; 106(1):90-95.

    Article  PubMed  CAS  Google Scholar 

  51. Rollison DE, Newschaffer CJ, Tao Y, Pollak M, Helzlsouer KJ. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int J Cancer 2006; 118(5):1279-1284.

    Article  PubMed  CAS  Google Scholar 

  52. Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Soderberg S, et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 2002; 13(4):307-316.

    Article  PubMed  Google Scholar 

  53. Shi R, Yu H, McLarty J, Glass J. IGF-I and breast cancer: a meta-analysis. Int J Cancer 2004; 111(3):418-423.

    Article  PubMed  CAS  Google Scholar 

  54. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schunemann HJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002; 11(11):1361-1368.

    PubMed  CAS  Google Scholar 

  55. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993; 29A(4):492-497.

    Article  PubMed  CAS  Google Scholar 

  56. Vadgama JV, Wu Y, Datta G, Khan H, Chillar R. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the pro- gression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 1999; 57(4): 330-340.

    Article  PubMed  CAS  Google Scholar 

  57. Coskun U, Gunel N, Sancak B, Gunel U, Onuk E, Bayram O, et al. Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients. Breast 2003; 12(2): 104-110.

    Article  PubMed  Google Scholar 

  58. Holdaway IM, Mason BH, Lethaby AE, Singh V, Harvey VJ, Thompson PI, et al. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ J Surg 2003; 73(11):905-908.

    Article  PubMed  Google Scholar 

  59. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer 1996; 74(8):1242-1247.

    PubMed  CAS  Google Scholar 

  60. Mizukami Y, Nonomura A, Yamada T, Kurumaya H, Hayashi M, Koyasaki N, et al. Immunohistochemical demonstration of growth factors, TGF-alpha, TGFbeta, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res 1990; 10(5A):1115-1126.

    PubMed  CAS  Google Scholar 

  61. W Al-Sarakbi, Chong Y, Williams S, Sharma A, Mokbel K. The mRNA expression of IGF-1 and IGF-1R in human breast cancer: association with clinico-pathological parameters. J Carcinog 2006; 5:16.

    Article  PubMed  CAS  Google Scholar 

  62. Toropainen E, Lipponen P, Syrjanen K. Expression of insulin-like growth factor I (IGF-I) in female breast cancer as related to established prognostic factors and long-term prognosis. Eur J Cancer 1995; 31A(9):1443-1448.

    Article  PubMed  CAS  Google Scholar 

  63. Eppler E, Zapf J, Bailer N, Falkmer UG, Falkmer S, Reinecke M. IGF-I in human breast cancer: low differentiation stage is associated with decreased IGF-I content. Eur J Endocrinol 2002; 146(6):813-821.

    Article  PubMed  CAS  Google Scholar 

  64. Torrisi R, Decensi A, Formelli F, Camerini T, De PG. Chemoprevention of breast cancer with fenretinide. Drugs 2001; 61(7):909-918.

    Article  PubMed  CAS  Google Scholar 

  65. Fabian CJ, Kimler BF. Chemoprevention for high-risk women: tamoxifen and beyond. Breast J 2001; 7(5):311-320.

    Article  PubMed  CAS  Google Scholar 

  66. Friedl A, Jordan VC, Pollak M. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993; 29A(10):1368-1372.

    Article  PubMed  CAS  Google Scholar 

  67. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Project- ing individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81(24):1879-1886.

    Article  PubMed  CAS  Google Scholar 

  68. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91(21):1829-1846.

    Article  PubMed  CAS  Google Scholar 

  69. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998; 90(19):1461-1467.

    Article  PubMed  CAS  Google Scholar 

  70. Bonanni B, Ramazzoto F, Franchi D, et al. A randomised trial of fenretinide in HRT users using IGf-1 as a surrogate biomarker. (abstract). Breast Cancer Res Treat. 2000; A152.

    Google Scholar 

  71. Kao PC, Matheny AP, Jr., Lang CA. Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab 1994; 78(2):310-312.

    Article  PubMed  CAS  Google Scholar 

  72. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996; 98(11): 2612-2615.

    Article  PubMed  CAS  Google Scholar 

  73. Comuzzie AG, Blangero J, Mahaney MC, Haffner SM, Mitchell BD, Stern MP, et al. Genetic and environmental correlations among hormone levels and measures of body fat accumulation and topography. J Clin Endocrinol Metab 1996; 81(2):597-600.

    Article  PubMed  CAS  Google Scholar 

  74. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998; 83(7):2286-2290.

    Article  PubMed  CAS  Google Scholar 

  75. Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001; 10(4):377-384.

    PubMed  CAS  Google Scholar 

  76. Jernstrom H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor1: implications for premenopausal breast cancer risk. Mol Genet Metab 2001; 72 (2):144-154.

    Article  PubMed  CAS  Google Scholar 

  77. Jernstrom H, Sandberg T, Bageman E, Borg A, Olsson H. Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. Br J Cancer 2005; 92(5):857-866.

    Article  PubMed  CAS  Google Scholar 

  78. Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, et al. A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer 2002; 100(3):332-336.

    Article  PubMed  CAS  Google Scholar 

  79. Maskarinec G, Williams AE, Kaaks R. A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 2003; 107(6):991-996.

    Article  PubMed  CAS  Google Scholar 

  80. Hartmann BW, Laml T, Kirchengast S, Albrecht AE, Huber JC. Hormonal breast augmentation: prognostic relevance of insulin-like growth factor-I. Gynecol Endocrinol 1998; 12(2):123-127.

    Article  PubMed  CAS  Google Scholar 

  81. Dupont WD, Page DL. Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidemiol 1987; 125(5):769-779.

    PubMed  CAS  Google Scholar 

  82. Jernstrom H, Olsson H. Breast size in relation to endogenous hormone levels, body constitution, and oral contraceptive use in healthy nulligravid women aged 19-25 years. Am J Epidemiol 1997; 145(7):571-580.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast & Endocrine Surgery, St. George's Hospital, SW17 0QT, London, UK

    Yoon M. Chong

  2. Department of Breast & Endocrine Surgery, St. George's Hospital, SW17 0QT, London, UK

    Ash Subramanian

  3. The Princess Grace Hospital, 42–52 Nottingham Place, W1U 5NY, London, UK

    Kefah Mokbel MB BS, MS, FRCS

Authors
  1. Yoon M. Chong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ash Subramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kefah Mokbel MB BS, MS, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, Cardiff University School of Medicine, Heath Park, CF14 4XN, Cardiff, UK

    Robert E. Mansel MS, FRCS, CBE

  2. Michell Cancer Institute, University of South Alabama, 307 N. University Blvd., 2015, 36688, AL, USA

    Oystein Fodstad PhD

  3. Metastasis and Angiogenesis Research Group, Cardiff University School of Medicine, CF14 4XN, Heath Park, Cardiff, UK

    Wen G. Jiang MB, BCh, MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer

About this chapter

Cite this chapter

Chong, Y.M., Subramanian, A., Mokbel, K. (2007). The insulin-like growth factor-1 ligand in breast cancer management. In: Mansel, R.E., Fodstad, O., Jiang, W.G. (eds) Metastasis of Breast Cancer. Cancer Metastasis – Biology and Treatment, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-5867-7_10

Download citation

Publish with us

Policies and ethics

Search

Navigation